You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Osteoporosis

Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • Reference number: TA160
  • Published:  27 October 2008
  • Last updated:  07 February 2018
  • Guidance
  • Tools and resources
  • Evidence
  • History

TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014

TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014 TA161 Osteoporosis - secondary prevention including strontium ranelate: Appendix B - GE decision paper - March 2014
24 March 2014
(309.46 Kb 30 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 21 March 2014

Back to top